Research into multiple system atrophy (MSA) focuses on identifying the underlying causes of nerve cell damage. Some studies focus on how to prevent a build-up of the protein alpha-synuclein that interferes with nerve signals to the muscles and occurs in Parkinson’s disease. In addition, clinical trials for MSA investigate how various drug therapies can help relieve symptoms. New drugs being tested include the monoamine oxidase B inhibitor Rasagiline and the antibiotic Rifampicin. New diagnostic protocols help doctors identify the disease earlier.